Israel Englander’s Forte Biosciences FBRX Stock Holding History

Israel Englander’s Portfolio FBRX Stock Details FBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-500	Closed	-$37K	–	6971
2021 Q3	$37K	Buy	+500	New	+$277K	﹤0.01%	6617

Other funds holding FBRX

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Israel Englander's FBRX Position: Q2 2026 in Review

Israel Englander increased its Forte Biosciences (FBRX) stake by 94% in Q2 2026, buying an estimated $7.52M and bringing the position to 655,199 shares worth $13.9M. The position accounts for 0.01% of the portfolio, ranked #1964.

Israel Englander first reported a position in FBRX in Q1 2018 and has held it in 23 quarters since. 86 funds tracked by Wall St. Rank hold FBRX as of Q2 2026.

Israel Englander held 655,199 shares of Forte Biosciences worth $13.9M as of Q2 2026.
Israel Englander bought 317,216 Forte Biosciences shares in Q2 2026, an estimated $7.52M.
Forte Biosciences made up 0.01% of Israel Englander's portfolio in Q2 2026, its #1964 holding.
Israel Englander first reported a position in Forte Biosciences in Q1 2018 and has held it in 23 quarters since.
86 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.